ICON Launches New Analytics Service for Advanced Medical Review of Laboratory Data
News Nov 19, 2013
ICON plc has announced ICONIK Labs, the latest service to leverage its ICONIK technology platform.
ICONIK Labs is an interactive analytics tool that allows Clinical and Medical team members to visualize, analyze and report on large volumes of laboratory data in real time.
Using ICONIK Labs’ advanced visualization capabilities, project teams can interact with data and view trends at any level of detail, including patient, site, study or across an entire program through a series of dynamic filters.
ICONIK Labs enhances a study’s quality by instantly identifying sites with an unusual number of lab values outside the normal range and can also improve patient safety by providing Hy’s Law analysis which assists with the detection of subjects at risk of Drug Induced Liver Injury (DILI).
Commenting on the new service, Dr. Steve Cutler, Group President, ICON Clinical Research Services, said: “ICONIK Labs has transformed how study teams review and analyze laboratory data and has enabled a fresh approach to combining lab parameters to review study trends. It enables study teams to quickly uncover actionable insights that support earlier, more informed decision-making and more efficient trial management.”
ICONIK Labs is the latest service to leverage the ICONIK technology platform and follows ICON’s recent announcement of ICONIK Monitoring and ICONIK Patient Safety.
ICONIK Monitoring is a new service that improves quality and reduces the costs of clinical development through more effective use of monitoring resources.
ICONIK Patient Safety enables real-time analysis of aggregated patient safety data, giving study teams the ability to uncover potential medical issues in real-time.
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
IONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE AntibodiesNews
The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.READ MORE
Comments | 0 ADD COMMENT
2nd International Conference and Exhibition on Nanomedicine and Drug Delivery
May 21 - May 23, 2018
World Congress on Advanced Biomaterials and Tissue Engineering
Jun 20 - Jun 21, 2018